Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: Systemic sclerosis is a chronic multisystemic disease characterized by vascular disorders, immune activation, organ and tissue fibrosis. Methods: Descriptive study. Patients diagnosed with systemic sclerosis who met the criteria ACR- EULAR classification 2013, that receive medical care at Carlos Andrade Marín hospital. Results: Prevalence: From 80 patients,18 had systemic sclerosis, full CREST form; 32 had incomplete CREST form; 14 had a diffuse form; one had systemic sclerosis without cutaneous impairment; 13 had overlaping syndrome and two EMTC. Discusion: Clinical and epidemiological characteristics of our patients were consistent with those described in the medical literature.
Seibold J. Esclerodermia y enfermedades del tejido conjuntivo. En Ruddy S, Harris E, Sledge C, et al. Kelley’s Textbook of Rheumatology. 6ta edn. Madrid. Marbán Libros 2003. 1211- 1239.
Kowal O, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620–628.
Cottrell T, Wise R, Wigley F, et al. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 2014; 73: 1060-1066.
Gabrielli A, Avvedimento E, Krieg T. Mechanisms of Disease Scleroderma. N Engl J Med 2009; 360:1989-2003.
Rojas J. Epidemiología. Diferencias étnicas en la esclerosis sistémica. Reumatol Clin 2006; 2 Supl 3:S2-5.
Alarcón D, et al. Tratado Hispanoamericano de Reumatología. Bogotá – Colombia: Nomos 2006: 885-922.
Lawrence R, Hochberg M, Kelsey J, et al.
Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J. Rheumatol 1989; 16: 427- 441
Sánchez J, Castillo M, García F. Esclerosis Sistémica. Enfermedades Autoinmunes Sistémicas. Asociación de Autoinmunes y Lupicos de Sevilla. España: Coria Gráfica. 2010: 109 - 128.
Van den Hoogen F, et al. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Classification Criteria for Systemic Sclerosis. Arthritis & Reumatism 2013: 1 - 11. www.arthritisrheum.org and wileyonlinelibrary.com.
Méndez A. Esclerosis Sistémica. Rev Cl EMed UCR. 2013; 3: 15-26.
Diagnóstico, Tratamiento y Pronóstico de la Esclerosis Sistémica. México: Secretaría de Salud, 2010. www.cenetec.salud.gob.mx/interior/ gpc.html.
Nitsche A. Revisión. Raynaud, úlceras digitales y calcinosis en esclerodermia. Reumatol Clin. 2012; 8(5): 270–277.
Garza V, Villarreal M, Ocampo J. Etiopatogenia y tratamiento de la esclerodermia Conceptos actuales. Rev Med Inst Mex Seguro Soc. 2013; 51(5): 50-7.
Tashkin D et al. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. N Engl J Med 2006; 354: 2655-66.
Derk C et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009; 48: 1595–1599.
Iglesias A et al. Historia del compromiso cutáneo de la esclerosis sistémica. REV COLOMB REUMATOL. 2013; 20(3): 155-170.
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.